Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Cabaletta Bio, a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that CEO Steven Nichtberger will present at the 41^st Annual J.P. Morgan Conference on January 12^th at 7:30 a.m. PT in San Francisco. A live webcast will be available on the company’s website, and replays will be accessible for 30 days. Cabaletta Bio aims to develop potentially curative therapies through its CABA™ platform, which includes lead candidates CABA-201 and DSG3-CAART for conditions like mucosal pemphigus vulgaris.

PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will present at the 41^st Annual J.P. Morgan Conference being held in San Francisco, CA on Thursday, January 12^th at 7:30 a.m. PT (10:30 a.m. ET).

A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days.

About Cabaletta Bio

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing CD19-CAR T, as the lead product candidate, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform may offer potentially curative therapies for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters are located in Philadelphia, PA.

Contacts

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

FAQ

What is the date and time of Cabaletta Bio's presentation at the J.P. Morgan Conference?

Cabaletta Bio's presentation at the J.P. Morgan Conference is scheduled for January 12^th at 7:30 a.m. PT.

Where can I watch the live webcast of Cabaletta Bio's presentation?

The live webcast of Cabaletta Bio's presentation will be available on their official website in the News and Events section.

What is the focus of Cabaletta Bio's CABA™ platform?

Cabaletta Bio's CABA™ platform focuses on developing engineered T cell therapies for treating autoimmune diseases.

What is the lead product candidate of Cabaletta Bio?

The lead product candidate of Cabaletta Bio is CABA-201, which is a 4-1BB-containing CD19-CAR T.

How long will the presentation replay be available?

The replay of Cabaletta Bio's presentation will be available for 30 days on their website.